法国大规模德尔菲共识:ctDNA分析技术建议——迈向欧洲 Harmonization
法国肿瘤细胞遗传学组(GFCO)开展欧洲迄今最大规模德尔菲共识,涉及39个高流量分子平台(应答率71%),通过迭代匿名调查和现场投票形成37条推荐(同意率≥80%),覆盖分析前、分析中、生物信息学和分析后阶段。关键共识包括强制使用UMI并倾向连接法引入(95-100%)、双离心并以高速二次离心、系统阳性对照模拟ctDNA特征、保留白细胞等分用于克隆性造血评估,以及明确报告VAF、CHIP风险和阴性结果局限性。推荐与ESMO(2022)、ELBS(2025)、ISLB(2025)和AMP/CAP指南一致性超过90%,并在UMI实施、血浆储存、离心参数等关键步骤提供更具操作性的规范。
要点
- 强制使用UMI,倾向连接法引入(95-100%同意)
- 双离心并以高速二次离心处理血浆
- 系统阳性对照需模拟ctDNA特征
核心结论
- 该共识提供稳健、可立即实施的框架,补充并细化现有国际标准,为欧洲及更广泛地区ctDNA检测协调化铺路,增强液体活检在常规诊断和治疗诊断应用中的可信度。
研究设计与样本
- GFCO开展的欧洲迄今最大规模德尔菲共识,涉及39个高流量分子平台(应答率71%),采用迭代匿名调查和现场投票。
主要发现
- 形成37条推荐(同意率≥80%),覆盖分析前、分析中、生物信息学和分析后阶段。
- 关键共识包括强制使用UMI并倾向连接法引入(95-100%同意)、双离心并以高速二次离心、系统阳性对照模拟ctDNA特征、保留白细胞等分用于克隆性造血评估、明确报告VAF、CHIP风险和阴性结果局限性。
- 推荐与ESMO(2022)、ELBS(2025)、ISLB(2025)和AMP/CAP指南一致性超过90%。
关键数值与推荐
- 37条推荐均达到≥80%同意率。
- UMI使用及连接法引入的同意率为95-100%。
- 与ESMO(2022)、ELBS(2025)、ISLB(2025)和AMP/CAP指南一致性超过90%。
临床怎么用
- 在ctDNA检测全流程中实施UMI(倾向连接法引入),采用双离心并以高速二次离心处理血浆。
- 设置模拟ctDNA特征的系统阳性对照,保留白细胞等分用于克隆性造血评估。
- 报告需明确VAF、CHIP风险和阴性结果局限性,以支持常规诊断和治疗诊断决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating tumour DNA (ctDNA) testing by liquid biopsy has become a cornerstone of precision oncology, yet technical heterogeneity across laboratories continues to hamper reproducibility and clinical reliability. METHODS: To address this challenge, the Groupe Français de Cytogénétique Oncologique (GFCO) conducted the largest European Delphi consensus initiative to date on technical standardization of ctDNA analysis, involving 39 high-volume molecular platforms (71 % response rate). RESULTS: Using iterative anonymous surveys and live voting, we established 37 recommendations (≥80 % agreement) spanning pre-analytical, analytical, bioinformatics, and post-analytical phases. Key consensus points include mandatory use of unique molecular identifiers (UMIs) with preference for ligation-based incorporation (95-100 %), double centrifugation with high-speed second spin, systematic positive controls mimicking ctDNA characteristics, leukocyte aliquot preservation for clonal haematopoiesis evaluation, and explicit reporting of variant allele frequency, CHIP risk, and limitations of negative results. These recommendations demonstrate more than 90 % alignment with recent ESMO (2022), ELBS (2025), ISLB (2025), and AMP/CAP guidelines while providing more prescriptive, operationally oriented specifications on critical steps (e.g., UMI implementation, plasma storage, centrifugation parameters) that address real-world gaps repeatedly identified in European external quality assessment schemes. CONCLUSIONS: By offering a robust, ready-to-implement framework that complements and refines existing international standards, this consensus paves the way for broader harmonization of ctDNA testing across Europe and beyond, ultimately strengthening confidence in liquid biopsy results for routine diagnostic and theragnostic applications in oncology.
引用
- Harlé A, Payen L, Lespagnol A, et al. Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis. Eur J Cancer. 2026. PMID: 42190398. doi:10.1016/j.ejca.2026.116791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。